Endeavor BioMedicines receives Orphan Drug Designation for taladegib (ENV-101) in IPF by mariel | Jul 16, 2025 | Portfolio NewsEndeavor announced Orphan Drug Designation from both the European Commission and U.S. FDA for taladegib (ENV-101) for idiopathic pulmonary fibrosis; the company is enrolling WHISTLE-PF (Phase 2b).
Kestra Medical Technologies Announces Inclusion in the Russell 2000® and Russell 3000® Indexes by Carolyn Helms | Jun 23, 2025 | Portfolio News
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank by Carolyn Helms | Jun 17, 2025 | Portfolio News
Cohere Health’s Review Assist Accelerates Clinical Reviews for Health Plans with Precision AI by Carolyn Helms | Jun 16, 2025 | Portfolio News
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia by Carolyn Helms | Jun 5, 2025 | Portfolio News
